The Board of Directors of the Ovarian Cancer Research Fund (OCRF) is pleased to announce that Jeff Boyd, PhD, Chief Scientific Officer at the Fox Chase Cancer Center in Philadelphia, PA, has been appointed Chair of the OCRF Scientific Advisory Committee (SAC).
The Scientific Advisory Committee is charged with evaluating research proposals to ensure that OCRF’s funding is directed to the most promising and innovative ovarian cancer research. “We are very fortunate to have a SAC that is composed of leaders in the field of ovarian cancer research, and who give so generously of their time to advance OCRF’s mission,” said Carmel Cohen, MD, who is Scientific Director of the OCRF. “We periodically rotate the position of Chair, and are so pleased that Jeff Boyd has accepted the position. Like every member of the Committee, Dr. Boyd is exceptionally well qualified to lead the Committee — and the organization — forward.”
Dr. Boyd has served as a member of the SAC since 2000. Boyd is an international expert in translational research and has particular expertise in the genetics of ovarian cancer, as well as other women’s cancers. He has helped define the role of tumor suppressors and oncogenes in these malignancies, most notably the p53, BRCA1 and BRCA2 tumor suppressor genes and their role in the development of breast cancer and ovarian cancer.
Before joining Fox Chase in 2008, Boyd was director of the Curtis and Elizabeth Anderson Center Institute and vice president of oncology and research at the Memorial University Medical Center in Savannah, Georgia. He also served as the professor of medicine, surgery, obstetric and gynecology at the Mercer University School of Medicine. At Mercer University, he served as the assistant dean of research.
Stay tuned for an interview with Dr. Boyd next month!